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Epilepsy is a common affliction that involves inflammatory processes. There are currently
no definitive chemical diagnostic biomarkers in the blood, so diagnosis is based on a some-
times expensive synthesis of clinical observation, radiology, neuro-psychological testing,
and interictal and ictal EEG studies. Soluble ICAM5 (sICAM5), also known as telencephalin,
is an anti-inflammatory protein of strictly central nervous system tissue origin that is
also found in blood. Here we have tested the hypothesis that plasma concentrations of
select inflammatory cytokines, including sICAM5, might serve as biomarkers for epilepsy
diagnosis. To test this hypothesis, we developed a highly sensitive and accurate electro-
chemiluminescent ELISA assay to measure sICAM5 levels, and measured levels of sICAM5
and 18 other inflammatory mediators in epilepsy patient plasma and controls. Patient sam-
ples were drawn from in-patients undergoing video-EEG monitoring, without regard to
timing of seizures. Differences were defined by t -test, and Receiver Operating Condition
(ROC) curves determined the ability of these tests to distinguish between the two pop-
ulations. In epilepsy patient plasmas, we found that concentrations of anti-inflammatory
sICAM5 are reduced (p=0.002) and pro-inflammatory IL-1β, IL-2, and IL-8 are elevated.
TARC (thymus and activation regulated chemokine, CCL17) concentrations trend high. In
contrast, levels of BDNF and a variety of other pro-inflammatory mediators are not altered.
Based on p-value and ROC analysis, we find that the ratio of TARC/sICAM5 discriminates
accurately between patients and controls, with an ROC Area Under the Curve (AUC) of
1.0 (p=0.034). In conclusion, we find that the ratio of TARC to sICAM5 accurately dis-
tinguishes between the two populations and provides a statistically and mechanistically
compelling candidate blood biomarker for drug resistant epilepsy.
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INTRODUCTION
Epilepsy affects up to 1% of the world’s population (Hauser et al.,
1993). There are currently no definitive chemical diagnostic bio-
markers in blood, so diagnosis is based on a sometimes expensive
synthesis of clinical observation, radiology, neuro-psychological
testing, and interictal and ictal EEG studies (Engel, 2001, 2011;
England et al., 2012). Past attempts to solve this problem have
focused on changes in blood concentrations of neuroendocrine
hormones, markers of central nervous system tissue (CNS) injury,
and more recently inflammation (Abbott et al., 1980; Palmio et al.,
2008). In recent rodent studies, pro-inflammatory and cellular
immune processes have been invoked as significant mediators
of seizure activity (Vezzani and Granata, 2005; Maroso et al.,
2010). This focus on inflammation has been productive, with
some groups finding altered cytokine levels in epilepsy patient
blood samples, including changes that seem to track with suc-
cessful epilepsy treatment (Lehtimaki et al., 2007, 2010; Alapirtti
et al., 2009, 2012; Iyer et al., 2010; Majoie et al., 2010). However,
the previously published candidate inflammatory biomarkers are
typically produced by non-CNS tissues, so a highly specific blood
biomarker for epilepsy, of unambiguous CNS origin, remains to
be discovered (Aronica and Crino, 2011).
Here we have focused our attention on the anti-inflammatory
soluble fraction of telencephalin (sICAM5), a protein which is pro-
duced normally only in the hippocampus and forebrain (Yoshihara
and Mori, 1994; Tian et al., 2008). In vitro, sICAM5 inactivates T-
cells (Tian et al., 2008). T-cells are important in the development
of epilepsy in the pilocarpine induced status epilepticus model
(Fabene et al., 2008). In the past, relatively insensitive assays for
sICAM5 had detected it in a small subset of epilepsy patients
(Rieckmann et al., 1998; Jansen et al., 2008). In contrast, we have
discovered that plasma sICAM5 is readily detected, and we have
therefore reassessed plasma sICAM5 as a biomarker for epilepsy
diagnosis using a new, highly sensitive assay.
Consistent with the pro-inflammatory model of drug resistant
epilepsy, our data show that patient plasma has low concentra-
tions of the anti-inflammatory sICAM5 and high concentrations
of some pro-inflammatory mediators. In addition, we find that
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the ratio of TARC (thymus and activation regulated chemokine,
CCL17) to sICAM5 constitutes a compelling candidate proteomic
signature for treatment-resistant epilepsy.
MATERIALS AND METHODS
PATIENTS
We collected plasma samples from in-patients already undergoing
epilepsy monitoring for clinical care at the Hospital of the Uni-
versity of Pennsylvania between January and August of 2010. All
patients gave informed consent for the study, which was approved
in advance by the University of Pennsylvania’s institutional review
board (IRB).
The diagnosis of focal epilepsy was confirmed by ictal EEG
recordings. The majority of control samples used in this research
were purchased from Innovative Research, and additional samples
were collected at the National Institutes of Health (NIH) under
a separate IRB approved protocol. The NIMH samples were all
from individuals who had been first qualified as healthy controls
by board certified psychiatrists, and were diagnosed as psychiatri-
cally and physically normal. The commercial plasma samples were
from donors, said to be free of physical or psychiatric disease. None
of the controls were known to be on antiepileptic drugs.
BLOOD COLLECTION AND PLASMA PREPARATION
The blood samples collected from epilepsy patients were interic-
tal and not correlated with the timing of patients’ seizures. The
samples were anticoagulated using Na-citrate and briefly trans-
ported on ice. The plasma was prepared by centrifuging samples
at 5,000× g for 15 min at 4˚C, and the supernatant solutions were
then aliquoted and stored at−80˚C.
Blood samples from the NIH were collected at 9 a.m. from
control patients also using Na-citrate as the anticoagulant. Fol-
lowing centrifugation, the supernatant solutions were aliquoted
and frozen at −80˚C. Plasma samples purchased from the two
commercial vendors were also anticoagulated with Na-citrate. Dif-
ferences among sets of controls were not significant (p< 0.05) and
the controls were grouped together.
ASSAY OF TELENCEPHALIN/sICAM5
Levels of immunoreactive Telencephalin/sICAM5 in plasma were
measured by sandwich ELISA using electrochemiluminescence
detection. Assays were carried out on high bind SECTOR® Imager
6000 reader plates (Meso Scale Discovery, Gaitherburg, MD, USA)
as follows. Wells were coated overnight with protein G affinity
purified mouse monoclonal anti-human sICAM5 antibody (cap-
ture antibody; R&D Systems, Minneapolis, MN, USA; catalog #
MAB 1950), 2µg/mL diluted in phosphate buffered saline (PBS;
25µL/well). Wells were emptied and then blocked for 2 h with
10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA)
in PBS (PBS-10% FBS). Wells were washed 3× with PBS con-
taining 0.05% tween-20 (PBS-T) and samples were introduced
into the wells in a total volume of 100µL consisting of 25µL
human plasma and 75µL PBS-5% FBS. ICAM5 standard curves
were prepared similarly in buffer containing 25µL equine plasma
(human ICAM5-free; Invitrogen, Carlsbad, CA, USA), to con-
trol for the affects of sample matrix. Plates were incubated for
3 h, washed and then incubated for 1 h with biotinylated goat
anti-human ICAM5 antibody purified by human ICAM5 affinity
chromatography (R&D Systems; catalog #BAF1950; 1µg/mL in
PBS-1% FBS; 25µL/well). Plates were washed and reacted for 1 h
with MSD® SULFO-TAG labeled streptavidin detection reagent
(Meso Scale Discovery; catalog# R32AD; 1µg/mL in PBS con-
taining 1% bovine serum albumin (BSA); 25µL/well). Plates were
washed, treated with the addition of MSD Read Buffer (Meso Scale
Discovery; catalog# R92TC; 150µL/well) and electrochemilumi-
nescence read using a SECTOR® Imager 6000 instrument (Meso
Scale Discovery). All incubations were carried out at room temper-
ature with the exception of that for the capture antibody which was
carried out at 4˚C. The assay was sensitive to less than 0.34 ng/mL
as defined by the electrochemiluminescence signal value that was
10× the standard deviation above the mean electrochemilumi-
nescence signal recorded for the 0 ng ICAM5 standard (N = 10).
The Z score for this assay is 0.92 (see Statistics in Materials and
Methods for calculation).
ASSAY OF CYTOKINES AND CHEMOKINES
Two multiplexed assays for cytokines and chemokines were used
for analysis of patient and control plasma samples on the SEC-
TOR® Imager 6000 instrument (Meso Scale Discovery, Gaither-
burg, MD, USA). The first of these assays was the Human Pro-
Inflammatory 9 Plex Assay (MesoScale catalog #K15007C-4) for
the measurement of IL-2, IL-8, IL-12p70, IL-1β, GM-CSF, IFN-
γ, IL-6, IL-10, and TNF-α. The second of these assays was the
Human Chemokine 9 Plex Assay (MesoScale catalog #K15001C-
1) for the measurement of Eotaxin, Eotaxin-3,MIP-1β, MCP-1,
MCP-4, TARC, IP-10, IL-8, and MDC, and was used. The samples
were added to plates that were pre-coated with capture antibodies
for the specific cytokines. The plates was sealed and shaken at room
temperature for 2 h. The plates was washed in PBS+ 0.05% Tween-
20 and detection antibody solution (1× or 1µg/mL) was added.
The plates were once again sealed and set to shake at room temper-
ature for 2 h. The plate was then washed once more in PBS+ 0.05%
Tween-20. Read buffer was added at a 2× concentration and the
plate was read on the SECTOR@ 6000 Imager.
Levels of immunoreactive BDNF in plasma were measured in a
manner similar to sICAM5 using antibodies and BDNF standard
protein provided in the R&D Systems human BDNF ELISA Devel-
opment Kit (catalog # DY248). Detection was by electrochemi-
luminescence using the MSD® SULFO-TAG labeled streptavidin
detection reagent and the SECTOR® Imager 6000. The assay was
sensitive to less than 0.08 ng/mL, as defined by the electrochemi-
luminescence signal value, which is 10× the standard deviation
above the mean electrochemiluminescence signal recorded for the
0 ng BDNF standard (N = 10).
STATISTICAL ANALYSIS
Differences in levels between epilepsy samples and normal con-
trols were calculated using a two-tailed t -test, except where indi-
cated, and taken to be significant at the p≤ 0.05 level, or ≥2
standard deviations (SD) from the mean (SD≥ 2.0), as appro-
priate. Receiver Operating Condition (ROC) curves were calcu-
lated and plotted (Srivastava et al., 2011). Z -scores for the new
sICAM5 and BDNF assays were calculated from the equation
Z = 1−3[(SD,1+ SD,2)/(µ2−µ1)], where SD,1 is one standard
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deviation from the mean of the blank; SD,2 is one standard devi-
ation from the mean of the signal; µ1 is the mean of the blank
and µ2 is the mean of the signal. Quality control was based on the
following criteria: (i) visual inspection of the multiplexed signals
revealed no defects; (ii) signal to noise ratio was>3; (iii) duplicate
assays agreed to within a coefficient of variation (CV) of <2.5%;
(iv) all data were greater than the lower limit of detection (LLOD).
RESULTS
CHARACTERISTICS OF THE SUBJECTS
All of the epilepsy patients were cognitively capable of giving
informed consent and all had partial onset seizures. The time from
seizure to blood draw was reliably known in six patients (average
23.3 h, range: 3–53). The patients’average age was 43.4 years (range
26–62), 50% were female, their average duration of epilepsy was
11 years (range 1–25), and their average number of seizures in the
day prior to blood draw was 21.1 (range 0–15).
Ninety percent of the epilepsy subjects had a left hemispheric
onset. The epilepsy patients had chronically been administered a
variety of antiepileptic drugs. One epilepsy patient had a diagnosis
of lupus and had received both Cellcept and Plaquenil and another
received montelukast sodium for asthma. No other patients were
known to be taking any potentially immune modulating therapy
(Table 1).
Controls were obtained from the NIH (n= 10) and from Inno-
vative Research (n= 20). Although the epidemiology and epilepsy
status of the controls are unknown, none were collected from an
epilepsy enriched population.
MEASUREMENT OF sICAM5 IN PLASMA FROM EPILEPSY PATIENTS
The median value of sICAM5 in control plasmas is 16± 4 (ng/mL)
while in epilepsy plasmas the value is 3.1± 1.2 (ng/mL). This
represents a 5.1-fold reduction in sICAM5 in epilepsy plasmas
compared to control plasmas. This difference between patients
and controls is also highly significant (p= 0.002). There is some
Table 1 | Epidemiology and clinical characteristics of the epilepsy
patients.
Patient Age Gender Duration of
epilepsy
(years)
AEDs Location
1 40 M 18 ZNS, PHT Left fronto-temporal
2 27 M 8 LVT, ZNS Left fronto-temporal
3 54 F 19 TPM, CZP Left fronto-temporal
4 62 M 1 OXC, CZP,
PGB
Left fronto-temporal
5 37 F Unknown LVT, TPM,
LCM
Left fronto-temporal
6 37 F 25 PHT, LZP Right frontal, poorly
localized
7 48 M Unknown PHT, OXC,
LVT, TPM
Left temporal
8 52 M 3 LVT, PHB,
TPM
Left hemisphere
9 51 F 11 OXC, ZNS Left temporal
10 26 F 3 LTG, ZNS Left temporal
overlap of values for plasma sICAM5 between epilepsy patients
and controls, and the ROC Area Under the Curve (AUC) of 0.87
(Figure 1; Table 2).
MEASUREMENT AND COMPOSITE RATIOS OF CYTOKINES AND
CHEMOKINES IN PLASMA FROM EPILEPSY PATIENTS
We used the MesoScale platform to measure 17 additional ana-
lytes. Five of these analytes had p-values< 0.05 when comparing
levels in epilepsy and control plasmas. In the order of decreasing
fold elevation, these included the following: IL-1β (3.5×)> IL-
2 (2.9×)> IFN-γ (2.2×)> IL-8(1.4×)> IL-12p70 (1.7× lower;
Table 2). Data were also obtained for TNF-α, MDC, BDNF, IL-10,
GM-CSF, MCP-1, MIP-1β, MCP-4, IP-10, Eotaxin-3, and Eotaxin,
but were not significant (Table 3).
Similar to result of sICAM5, none of these tested analytes dis-
criminated perfectly between the two populations. Therefore, we
attempted to create a composite biomarker with sICAM5 as one
of the elements. IL-6, IL-8, and TARC were included in this analy-
sis because of their high baseline concentrations, statistical trend
toward higher values in epilepsy patient plasma, and in the case of
IL-6, solid literature showing altered plasma concentration in the
epilepsy population.
The median value for IL-6 in control plasmas is
1.1± 0.2 pg/mL, while in epilepsy plasmas the value is 3.1± 1.3
pg/mL. The IL-6 p-value is 0.067, and the ROC curve has an AUC
of 0.81 (Figure 2; Table 2). When IL-6 is analyzed as a composite
ratio to sICAM5, the IL-6/sICAM5 ratio can discriminate between
epilepsy and control plasmas by a factor of 14.9-fold. However,
FIGURE 1 | Assay of sICAM5 in plasma from epilepsy patients and
controls. (A) Dot-plot of sICAM5 concentrations in plasma (square,
patients; diamond, controls). For values between the horizontal lines, the
assay does not accurately discriminate between patients and controls. (B)
Bar graph and error calculation for data in Part (A). Difference is significant
for p=0.002. (C) ROC curve for data in Part a, showing an area under the
curve (AUC) value of 0.87.
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Table 2 | Levels of cytokines and chemokines in plasma that significantly distinguish between epilepsy patients and controls.
Analyte Units Analyte concentration Ratio (E/C) p-Value AUC n Epi n con
Epilepsy Controls
sICAM5 ng/mL 3.1±1.2 16±4 ↓ 5.1 0.002 0.87 9 16
IL-1β pg/mL 0.2±0.1 0.1±0.0 ↑ 3.4 0.018 0.73 10 26
IL-6 pg/mL 3.1±1.3 1.1±0.2 ↑ 2.8 0.067 0.81 10 26
IL-2 pg/mL 0.7±0.2 0.3±0.0 ↑ 2.6 0.013 0.79 10 26
IFN-γ pg/mL 1.4±0.3 0.7±0.1 ↑ 2.1 0.014 0.76 10 26
TARC pg/mL 148±44 77±13 ↑ 1.9 0.068 0.72 8 9
IL-12p70 pg/mL 0.9±0.2 1.6±0.3 ↓ 1.7 0.038 0.59 10 24
IL-8* pg/mL 3.8±0.5 2.7±0.2 ↑ 1.4 0.020 0.75 10 27
TARC/sICAM5 (94±41)·103 (7.2±2.5)·103 ↑ 13.0 0.034 1.00 6 8
IL-6/sICAM5 (2.9±1.9)·103 (0.2±0.1)·103 ↑ 14.9 0.087 0.90 7 16
IL-8/sICAM5* (4.0±3.0)·103 (0.5±0.2)·103 ↑ 8.2 0.125 0.88 7 17
*IL-8 is the average of the values from the chemokine and the cytokine plates for each patient.
Bolded p-values are 0.05. Bolded AUC indicate >0.8.
Table 3 | Levels of cytokines and chemokines in plasma that do not significantly distinguish between epilepsy patients and controls.
Analyte Units Analyte concentration Ratio (E/C) p-Value AUC n Epi n con
Epilepsy Controls
TNF-α pg/mL 7.7±2.5 5.5±0.4 ↑ 1.4 0.188 0.59 10 25
MDC ng 2.6±0.4 2.2±0.2 ↑ 1.2 0.151 0.77 8 9
BDNF ng 0.8±0.2 1.0±0.2 ↓ 1.2 0.290 0.61 9 10
IL-10 pg/mL 1.4±0.2 1.8±0.3 ↓ 1.2 0.161 0.50 10 25
GM-CSF pg/mL 1.2±0.3 1.4±0.4 ↓ 1.2 0.303 0.56 10 24
MCP-1 pg/mL 238±41 219±13 ↑ 1.1 0.330 0.65 8 9
MIP-1β pg/mL 66.2±11.7 58±6 ↑ 1.1 0.268 0.65 8 9
MCP-4 pg/mL 388±81 367±67 ↑ 1.1 0.419 0.52 8 9
IP-10 pg/mL 189±47 207±38 ↓ 1.1 0.377 0.56 8 9
Eotaxin-3 pg/mL 5.9±0.8 6.4±1.1 ↓ 1.1 0.348 0.51 8 9
Eotaxin pg/mL 456±128 525±105 ↓ 1·1 0.334 0.55 8 9
the p-value is only 0.087, and the ROC curve for the IL-6/ICAM5
ratio has an AUC value of 0.90 (Figure 3; Table 2).
The median value for IL-8 in control plasmas is
2.7± 0.2 pg/mL, while in epilepsy plasmas the value is
3.8± 0.5 pg/mL; the difference between medians for IL-8 is only
1.4-fold. The p-value is 0.02 and the ROC curve has an AUC value
of 0.75 (Figure 4; Table 2). If IL-8 is analyzed as a composite
ratio to sICAM5, the IL-8/sICAM5 ratio can discriminate between
epilepsy and control plasmas by a factor of 8.2-fold (Figure 5).
However, the difference is not significant, based on the p-value of
0.125. Consistently, the substantial overlap evident in the dot-plot
results in an ROC curve for the IL-8/sICAM5 ratio that has an
AUC value of only 0.88 (Figure 5; Table 2).
The mean level of the chemokine TARC in control plasma is
77± 13 pg/mL, compared to 148± 44 pg/mL in epilepsy patient
plasma (Figure 6; Table 2). Epilepsy patient concentrations are
1.9-fold elevated in plasma TARC compared to control patients,
though this difference is not significant (p= 0.068). The ROC
analysis indicates that the AUC is 0.72 (Figure 6; Table 2). How-
ever, we found that the TARC/sICAM5 ratio is 13-fold higher in
epilepsy patients than controls (Figure 3; Table 2). The difference
is significant (p= 0.034), and the ROC curve shows that the AUC is
1.00 (Figure 7; Table 2), suggesting a robust statistical relationship
that distinguished epilepsy patients from controls.
DISCUSSION
In this paper we show that in drug resistant epilepsy patients, the
plasma concentration of sICAM5, a forebrain-derived inhibitory
T-cell regulator, is low while the concentrations of some pro-
inflammatory cytokines and chemokines are high. These data lend
support to the hypothesis that drug resistant epilepsy is associated
with inflammatory changes in plasma.
The ratio of the concentrations of two T-cell regulatory pro-
teins, TARC and sICAM5, is able to discriminate accurately drug
resistant epilepsy patients from controls. The TARC/sICAM5
ratio has a high fold-difference between epilepsy and controls
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FIGURE 2 | Assay of IL-6 in plasma from epilepsy patients and controls.
(A) Dot-plot of IL-6 concentrations in plasma (square, patients; diamond,
controls). For values between the horizontal lines, the assay does not
accurately discriminate between patients and controls. (B) Bar graph and
error calculation for data in Part (A). Difference is not significant for
p=0.067. (C) ROC curve for data in Part a, showing an area under the curve
(AUC) value of 0.81.
(13-fold), strong statistical significance (p= 0.034), and a perfect
ROC curve (AUC= 1.00; Figure 2; Table 2). We suggest that the
plasma TARC/sICAM5 ratio can be considered as a CNS-specific
candidate biomarker for drug resistant epilepsy.
LIMITATIONS OF THE DATA
We acknowledge some limitations in our dataset. For example,
the patient cohort, which is limited in size, consists entirely of
focal epilepsy patients, most of whom have left hemispheric foci.
In addition, age, gender, and seizure incidence were not taken
into account when selecting these patients for analysis. Further-
more, we have no CSF or brain tissue samples to confirm the
presence of inflammation in these patients, nor its absence in the
controls. Polytherapy with antiepileptic drugs was ubiquitous for
the studied patients, and it is possible that some or all of the drugs
could have affected the studied parameters. (Beghi and Shorvon,
2011) However, because this study lacks any epilepsy patients on
monotherapy or no therapy, delineating each drug’s effect on the
outcomes measured was beyond the capacity of this study. Finally,
two patients had received immunomodulatory drugs, which could
have confounded the findings. The same concerns could also
extend to the controls, which were obtained from two indepen-
dent sources. However, we suggest that the very generality of both
the patient and control cohorts might be a strength rather than a
limitation of this study. Despite the limitations of both cohorts,
the composite TARC/sICAM5 ratio has high fidelity to the epilepsy
diagnosis.
FIGURE 3 | IL-6/sICAM5 ratio in plasma from epilepsy patients and
controls. (A) Dot-plot of IL-6/sICAM5 concentrations in plasma (square,
patients; diamond, controls). For values between the horizontal lines, the
assay does not accurately discriminate between patients and controls. (B)
Bar graph and error calculation for data in Part (A). Difference is not
significant, with p=0.087. (C) ROC curve for data in Part (A), showing an
area under the curve (AUC) value of 0.90.
CNS SOURCE OF sICAM5
ICAM5 is also known as telencephalin because of its exclusive
location in the telencephalon. It is specifically excluded from all
γ-aminobutyric acid (GABA)-ergic interneurons at all stages of
development and is only present on glutamatergic neurons (Yoshi-
hara et al., 1994; Benson et al., 1998). ICAM5 is first expressed
around birth, both in mouse and in man, when dendritic out-
growth and branching, spine formation and synapse formation
are initiated in the forebrain, and it plays an active role in synapse
formation (Yoshihara et al., 1994; Arii et al., 1999; Furutani et al.,
2007). ICAM5 also interacts with LFA-1/α1β2 Integrin, like other
members of the ICAM family such as ICAM1 (Mizuno et al., 1997).
Brain microglia have LFA-1/α1β2 Integrin on their cell surfaces and
are activated by exposure to ICAM5 (Mizuno et al., 1999). Some
have suggested that ICAM5 serves a critical role in effective CNS
inflammation (Kipnis et al., 2004; Ziv et al., 2006; Schwartz and
Kipnis, 2011).
The only known source for soluble ICAM5 is from the cleavage
of membrane bound ICAM5 by matrix metalloproteinases, and
there are no described splice variants of ICAM5 (Conant et al.,
2010). The production of sICAM5 is known to occur during den-
dritic growth or glutamate activation (Tian et al., 2000, 2007). The
mechanism by which sICAM5 escapes the extracellular fluid and
crosses the blood brain barrier to enter the plasma has yet to be elu-
cidated. Since published CSF concentrations of sICAM5 are higher
than the plasma concentrations we found, it appears that there is
a homeostatic concentration gradient favoring transfer from the
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FIGURE 4 | Assay of IL-8 in plasma from epilepsy patients and controls.
(A) Dot-plot of IL-8 concentrations in plasma (square, patients; diamond,
controls). For values between the horizontal lines, the assay does not
accurately discriminate between patients and controls. (B) Bar graph and
error calculation for data in Part (A). Difference is 1.4-fold, and significant for
p= 0.020. (C) ROC curve for data in Part (A), showing an area under the
curve (AUC) value of 0.75.
CSF to the plasma (Lindsberg et al., 2002). Diffusion might be the
simplest explanation for the presence of sICAM5 in plasma.
The low sICAM5 concentration in epilepsy patient plasma
could help perpetuate the CNS pro-inflammatory environment
through a dearth of negative feedback (Lindsberg et al., 2002).
There is precedent for this type of ICAM inflammation feedback
loop in another tissue type, alveolar epithelial lung cells. In these
cells, the parent ICAM1 is critical to translocation of leukocytes for
maintaining immunity, while the cleavage product sICAM1 is part
of a negative feedback loop that moderates leukocyte translocation
through competition for β2 integrin binding (Kusterer et al., 1998;
Mendez et al., 2008). If the regulation of sICAM5 follows this type
of ICAM1 pattern, feedback could occur through inhibition of
T-cell activation and translocation, a mechanism consistent with
our findings of disease specific pro-inflammatory alterations in
the T-cell regulatory proteins TARC and sICAM5. Further inves-
tigation of this relationship might yield mechanistic insights into
the pathobiology underlying not only the physical manifestations
of epilepsy, but also the functional consequences of the ongoing
disease.
TARC AND OTHER NON-CNS SOURCE INFLAMMATORY MEDIATORS AS
BIOMARKERS OF EPILEPSY
Thymus and activation regulated chemokine (TARC/CCL17) is
produced by multiple immune cell types and is thought to be a
T-cell chemokine (Imai et al., 1996, 1997). Our data showed only
a trend toward TARC elevation in epilepsy patients (p= 0.06);
FIGURE 5 | IL-8/sICAM5 ratio in plasma from epilepsy patients and
controls. (A) Dot-plot of IL-8/sICAM5 concentrations in plasma (square,
patients; diamond, controls). For values between the horizontal lines, the
assay does not accurately discriminate between patients and controls. (B)
Bar graph and error calculation for data in Part (A). Difference not
significant, with p=0.125. (C) ROC curve for data in Part (A), showing an
area under the curve (AUC) value of 0.88.
however, in combination with sICAM5, the result was significant.
It is therefore possible that the two analytes may be reflective of
the same T-cell pro-inflammatory process.
Previously, cytokines and chemokines had been found to be
elevated in epilepsy patients, including high levels of IL-6 postic-
tally (Bauer et al., 2009). The mean values presented in this paper
differ from some previously published data examining epilepsy
patients’ blood cytokine levels (Peltola et al., 2000). This is likely
due to two different factors. First, the Peltola group used differ-
ent collection methods assaying blood soon after the seizure and
surveying a more heterogeneous population. Second, this study
uses more precise assays as evidenced by smaller error values. For
these reasons, it is difficult to compare the two studies directly. The
higher plasma levels observed in this study of IL-6, IL-1β, IL-2, and
IL-8, also support the concept that innate immunity is chronically
activated in epilepsy.
Interestingly there are also several reports of direct effects of
cytokines on excitability of brain tissue (Balosso et al., 2008;
Vezzani et al., 2008; Galic et al., 2012). For example, one study
delineates the relative attenuation of inhibitory neurotransmis-
sion distal to inflamed supporting cells (Ortinski et al., 2010). This
imbalance between excitation and inhibition could cause seizures.
If inflammation causes seizures then inflammatory mediators
are in the pathway of seizure generation. Plasma sampling of CNS
origin sICAM5 might then be used as a biomarker for predict-
ing important aspects of epilepsy care, such as recurrence, efficacy
of a new medicine, or perhaps even when a seizure might occur
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FIGURE 6 | Assay ofTARC in plasma from epilepsy patients and
controls. (A) Dot-plot of TARC concentrations in plasma (square, patients;
diamond, controls). For values between the horizontal lines, the assay does
not accurately discriminate between patients and controls. (B) Bar graph
and error calculation for data in Part (A). Difference is not significant for
p= 0.068. (C) ROC curve for data in Part (A), showing an area under the
curve (AUC) value of 0.72.
(Vezzani and Friedman, 2011). Future studies should explore this
possibility using postictal plasma sampling, expecting up regula-
tion of inflammation peri-ictally. In addition, a rigorous, larger
scale prospective study should be initiated to validate the discov-
ery of the TARC/sICAM5 ratio as a diagnostic tool for intractable
epilepsy.
In conclusion, this study has identified the CNS origin sICAM5
as an anti-inflammatory plasma protein that is low in epilepsy
patient plasma. In addition, the ratio of pro-inflammatory
TARC to anti-inflammatory sICAM5 is capable of discriminating
epilepsy patients from normal controls. We suggest that this ratio
constitutes a CNS-specific candidate biomarker for drug resistant
epilepsy. This should be evaluated further with future studies using
FIGURE 7 |TARC/sICAM5 ratio in plasma from epilepsy patients and
controls. (A) Dot-plot of TARC/sICAM5 concentrations in plasma (square,
patients; diamond, controls). There are no values between the horizontal
lines, indicating the assay accurately discriminates between patients and
controls. (B) Bar graph and error calculation for data in Part (A). Difference
is 13-fold, and is significant for p=0.034. (C) ROC curve for data in Part (A),
showing an area under the curve (AUC) value of 1.00.
larger patient cohorts with more diverse seizure localizations, peri-
and postictal plasma sampling, and demographic and antiepileptic
drug matched controls.
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